To celebrate the Common Drug Review’s 10th anniversary, the Canadian Agency for Drugs and Technologies in Health (CADTH) has created a video and series of graphics to simply and clearly explain the Common Drug Review process and how it helps 18 publicly funded drug plans make informed decisions when new drugs come to market.

Take a look at the video here:


There are similarities between how the Common Drug Review evaluates new drugs and how health care providers evaluate new medical technologies. Both ask the following three questions: Is it safe? How does it compare to existing treatments? Can we afford it?

See the graphics that explains how the Common Drug Review answers these questions>>

Answering the last two questions is less straightforward for medical devices, especially if they are new innovations that have no similarities to existing technologies. Also, depending on the technology the alternative treatment may not be another device but a surgical procedure or drug.

It is also important to evaluate the total cost of implementing a device- training, maintenance, and time which are some factors that are often missed in studies. That is why EXCITE has developed its core evidentiary bundle that is designed to answer these questions and more.

Applications to EXCITE are now open! For more information on eligibility criteria and how to apply, visit the “How to Apply to EXCITE” section.